search icon

    Market Snapshot

    • S&P Futures

      3,779.5

    • Dow Futures

      30,569

    • Nasdaq Futures

      11,622.75

    blog search icon

    BeiGene, Ltd.

    (NASDAQ:BGNE)

    $194.48

    $27.53

    16.49%

    BeiGene, Ltd. Chart

    BGNE Stock Price Today

    BeiGene, Ltd. (BGNE) stock rallied over 16.49% intraday to trade at $194.48 a share on NASDAQ. The stock opened with a gain of 21.69% at $173.57 and touched an intraday high of $196.4, rising 16.49% against the last close of $166.95. The stock went to a low of $171 during the session.

    Stock Snapshot

    $166.95

    Prev. Close

    21.63 Billion

    Market Cap

    $171

    Day Low

    $173.57

    Open

    102.46 Million

    Number of Shares

    $196.4

    Day High

    -

    P/E ratio

    -20.09

    EPS (TTM)

    64.45

    Cash Flow per Share

    2.95

    Free Float in %

    35.97

    Book Value

    475,322

    Volume

    BeiGene, Ltd. Historical Data

    DateOpenHighLowCloseVolume
    2022-07-05$173.57$196.4$171$194.48475,663
    2022-07-01$159.82$169.04$158.48$166.95225,100
    2022-06-30$158.94$162.6$154.8$161.85296,300
    2022-06-29$162.01$167.89$159.97$162.29371,900
    2022-06-28$167.8$171.31$160.04$165.03274,600
    2022-06-27$178.12$180.1$167.42$171.27255,500
    2022-06-24$169.53$181.83$166.35$177.99534,400
    2022-06-23$155.68$159.25$152.755$156.2202,800
    2022-06-22$148$159.72$148$155.68288,100
    2022-06-21$149.26$152.98$139.88$152.67836,100

    Contact Details

    Zhong-Guan-Cun Life Science Park
    No.30 Science Park Road Changping District
    Beijing 102206
    China

    Webiste:BGNE

    86 01 0851 48500

    Company Information

    Employees-

    Beta0.74

    Sales or Revenue1.18 Billion

    5Y Sales Change305.70%

    Fiscal Year Ends2021-12-30

    SectorHealth Care

    IndustryBiotechnology

    About Company

    BeiGene, Ltd. discovers, develops, manufactures, and commercializes medicines for cancer therapeutics in the People's Republic of China, the United States, and internationally. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; Pamiparib for the treatment of various solid tumors; and Pobevcy to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC). The company's clinical stage drug candidates comprise Zanubrutinib, a BTK inhibitor to treat lymphomas; Tislelizumab, an anti-PD-1 antibody to treat solid and hematological cancers; Lifirafenib and BGB-3245 to treat melanoma, NSCLC, and endometrial cancer; and Sitravatinib, a multi-kinase inhibitor to treat NSCLC, melanoma, and other solid tumors. Its clinical stage drug candidates also include BGB-A333, a PD-L1 inhibitor to treat various solid tumors; Ociperlimab, a TIGIT inhibitor to treat various solid tumors; BGB-11417, a small molecule Bcl-2 inhibitor to treat mature B-cell malignancies; BGB-A445, an OX40 agonist antibody to treat solid tumors; Zanidatamab, a bispecific HER2 inhibitor to treat breast and gastric cancer; BGB-A425, a T-cell immunoglobulin and mucin-domain containing-3 inhibitor to treat various solid tumors; and BGB-15025, a small molecule inhibitor of HPK1. BeiGene, Ltd. has strategic collaborations with Shoreline Biosciences, Inc., Amgen Inc., Novartis AG, and Bristol Myers Squibb company. BeiGene, Ltd. was incorporated in 2010 and is headquartered in Beijing, China.

    Frequently Asked Questions

    icon

    What is the current BeiGene, Ltd. (BGNE) stock price?

    BeiGene, Ltd. (NASDAQ: BGNE) stock price is $194.48 as of the last check on Tuesday, July 5. During the trading session, BGNE stock reached the peak price of $196.4 while $171 was the lowest point it dropped to.

    icon

    BGNE's industry and sector of operation?

    The NASDAQ listed BGNE is part of Biotechnology industry that operates in the broader Health Care sector. BeiGene, Ltd. discovers, develops, manufactures, and commercializes medicines for cancer therapeutics in the People's Republic of China, the United States, and internationally.

    icon

    Who are the executives of BGNE?

    Dr. Xiaodong Wang Ph.D.
    Co-Founder, Chairman of the Scientific Advisory Board & Non-Exec. Director
    Dr. Edna Huang M.D.
    Chief Medical Officer of Hematology
    Mr. John V. Oyler
    Co-Founder, Exec. Chairman & CEO
    Dr. Xiaobin Wu Ph.D.
    Pres, COO & GM of China

    icon

    What is the BGNE stock price today?

    BGNE stock traded closed the last session at $194.48, which is $27.53 or 16.49% lower than its previous close of $166.95. BGNE's current trading price is 64.56% lower than its 52-week high of $426.56 where as its distance from 52-week low of 118.18% is -54.41%.

    icon

    How many employees does BGNE have?

    Number of BGNE employees currently stands at -. BGNE operates from Zhong-Guan-Cun Life Science Park, No.30 Science Park Road Changping District, Beijing 102206, China.

    icon

    Link for BGNE official website?

    Official Webiste of $BGNE is: https://www.beigene.com

    icon

    How do I contact BGNE?

    BGNE could be contacted at BGNE operates from Zhong-Guan-Cun Life Science Park, No.30 Science Park Road Changping District, Beijing 102206, China, or at phone #86 01 0851 48500 and can also be accessed through its website.

    icon

    How many shares of BGNE are traded daily?

    BGNE stock volume for the day was 475,322 shares while in the previous session number of BGNE shares traded was 475,663 . The average number of BGNE shares traded daily for last 3 months was 283.47 Thousands.

    icon

    How much did BGNE change today?

    The percentage change in BGNE stock occurred in the recent session was 16.49% while the dollar amount for the price change in BGNE stock was $27.53.

    icon

    What price range BGNE stock been trading in?

    In the recent session, the day high for BGNE stock was $196.4 while the low for BGNE stock touched on the day was $171.

    icon

    What is the market cap of BGNE currently?

    The market value of BGNE currently stands at 21.63 Billion with its latest stock price at $194.48 and 102.46 Million of its shares outstanding.